Geron Corporation (NASDAQ: GERN) has released the data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper. The paper is entitled “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.”
The publication indicates the clinical advantages discovered in the study, comprising symptom response and overall survival, as well as the indication of disease-modifying activity from biomarker and bone marrow fibrosis assessments. The publication disclosed the efficacy, safety, and biomarker results from the IMbark Phase 2 clinical study. The firm has disclosed that the publication is available online.
Furthermore, IMpactMF is an open-label, randomized, controlled Phase 3 clinical study with registrational intent. The study is intended to register nearly 320 sufferers with Intermediate-2 or High-risk myelofibrosis who are refractory to before cure with a JAK inhibitor, also termed refractory MF.
Moreover, the firm disclosed that the current study is currently registering the participants. On a random basis, sufferers will get either imetelstat or the best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints comprise symptom response, spleen response, progression-free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and sufferers’ disclosed results.